Skip to content
  • About Us
  • Advertise
  • Contact Us
  • DMCA
  • Privacy Policy
  • Follow on Google News
The Medium News

The Medium News

  • Home
  • India
    • National
    • Regional News
  • Business
  • Education
  • LifeStyle
    • Fashion & Beauty
    • Food
    • Health & Fitness
    • Travel
  • Tech
    • Apps News
    • Gadgets
  • Automobiles
  • Sports
  • Entertainment
  • More
    • Agriculture
    • astrology
    • Environment
    • Finance/Money
    • Religion
    • Science
    • Social Work
    • Wow Personality
  • Toggle search form
Regrow Biosciences gets USFDA Nod for Phase II trials of 'OSSGROW' for Osteonecrosis in the US

Regrow Biosciences gets USFDA Nod for Phase II trials of ‘OSSGROW’ for Osteonecrosis in the US

Posted on June 4, 2022 By The Medium News No Comments on Regrow Biosciences gets USFDA Nod for Phase II trials of ‘OSSGROW’ for Osteonecrosis in the US

OSSGROW is India’s first FDA (DCGI) approved product that has treated over 1000 patients across 200 hospitals in the country

Mumbai (Maharashtra): Regrow Biosciences, an Indian-centric global biotech company, is glad to announce a breakthrough achievement of getting a USFDA nod for conducting a phase II trial of its lead product ‘OSSGROW,’ an orphan drug that helps in effectively treating  Osteonecrosis, in the US market. The accomplishment reflects the brand’s commitment to delivering a safe, effective, and durable solution to patients suffering from Osteonecrosis, also known as Avascular Necrosis. Furthermore, Regrow Biosciences moves one step closer to attaining a global market monopoly estimated at $5 Bn through this milestone feat.

Osteonecrosis is a prevalent disease in Asia. However, a rare disease in the United States and Europe. Regrow Biosciences has been granted Orphan Drug Designation (ODD) for OSSGROW ® from the USFDA and EMA. Furthermore, after completing Phase 3 clinical trials in India, OSSGROW® received marketing authorization from the Indian FDA (DCGI) in 2017; the product has successfully treated more than 1000 patients across 200 hospitals.

Speaking on the recent success, Mr. Satyen Sanghvi, Chief Scientific Officer and Executive Director at Regrow Biosciences Private Limited, said, “Regrow Biosciences welcomes the positive feedback from USFDA from its Pre-IND (Pre-Investigational New Drug) meeting to develop the world’s first biological bone cell therapy product – OSSGROW®, indicated to treat Osteonecrosis or Avascular Necrosis. The Pre-IND feedback and recommendation for Phase 2 clinical trial in a small patient population are very encouraging for the brand, as the company is now working towards IND filing. This positive feeling is backed by the safety and efficacy data of OSSGROW® across 200 hospitals in India for more than five years.”

Osteonecrosis, mainly seen in the hip joint, is a progressive bone disease that leads to the death of bone tissue due to interrupted blood supply. The initial stages are asymptomatic; however, the disease progresses quite rapidly, affecting the structure and eventually the function of the joint. The advanced stage involves the collapse of the femoral head and arthritis. This necessitates the patients who are barely in their 30s and 40s to undergo hip replacement surgery causing severe loss of productivity and decreased quality of life.

About Regrow Biosciences:

Regrow Biosciences Pvt. Ltd. is an Indian-centric global biotech company (www.regrow.in) with an R&D center and GMP manufacturing facility near Pune, India,  and offices in India, the US, and Singapore. The company is dedicated to researching, developing, and commercializing cell and stem cell-based products to target degenerative and life-threatening diseases. The company has crossed several milestones in its decade-long journey, with many firsts like market authorization and a commercial license for OSSGROW® and CARTIGROW® in 2017. UREGROW® was developed in collaboration with BIRAC, the Department of Biotechnology, the Ministry of Science and Technology, and the Government of India. Today with a strong pool of 340 doctor-partner networks across 46 cities, the Regrow Biosciences has transformed the lives of 1500 patients in India. In addition, the company also provides premium services for Cord Blood Stem Cell banking (Biocell®) across 600 Indian cities and has catered to more than 50,000 young parents.

Business Tags:Indian-centric global biotech company, Orphan Drug Designation (ODD), OSSGROW, Osteonecrosis, Regrow Biosciences, Regrow Biosciences Private Limited, Satyen Sanghvi

Post navigation

Previous Post: Creating pluralistic society is an important function of museums, public art
Next Post: Adi Pocha Launches his Debut Novel “Behram’s Boat” Published by Leadstart

More Related Articles

OSL Director Charchit Mishra bags ET’s “Influential Personality Award East 2023” for dynamic leadership in shipment & logistics Business
Vaibhav Global Limited launches ‘Draw A Design 2.0’ – A Jewelry Design Competition Business
Key Industry and Policy Makers Congregate at ACREX INDIA 2023 Key Industry and Policy Makers Congregate at ACREX INDIA 2023 Business
Unique Textile Business Model for Small Saree Sellers Unique Textile Business Model for Small Saree Sellers Business
Want to Know what others are thinking of you? Read their Minds Not the Signs Master Mentalism course at Rs. 399/- Want to Know what others are thinking of you? Read their Minds, Not the Signs. Master Mentalism course at Rs.399/- Business
Major Changes in NOC System under Express Entry Program for Canada – Explains Rudraksh Immigration Business

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Latest News

  • Want to Know what others are thinking of you? Read their Minds, Not the Signs. Master Mentalism course at Rs.399/-
  • Major Changes in NOC System under Express Entry Program for Canada – Explains Rudraksh Immigration
  • UCCIL Lauds Mahima Mishra’s Entrepreneurial Acumen, Philanthropic Spirit; Confers Coveted Award
  • Top Canada Immigration Consultants in India
  • ART Housing Finance Wins Three Prestigious Awards

Categories

  • Agriculture
  • Apps News
  • astrology
  • Automobiles
  • Business
  • Education
  • Entertainment
  • Environment
  • Fashion & Beauty
  • Finance/Money
  • Food
  • Gadgets
  • Health & Fitness
  • LifeStyle
  • National
  • Photography
  • Politics
  • Press Release
  • Regional News
  • Religion
  • Science
  • Social Work
  • Sports
  • Tech
  • Travel
  • Uncategorized
  • World
  • Wow Personality

Recent Posts

  • Japan-based Toyota Tsusho Corporation and Tokai Corp Partner to Launch Valabhi Hospital Services
  • Do rare Diseases account for the economic burden on India?
  • zPlus.care for all your healthcare needs
  • OSL Director Charchit Mishra bags ET’s “Influential Personality Award East 2023” for dynamic leadership in shipment & logistics
  • Vaibhav Global Limited launches ‘Draw A Design 2.0’ – A Jewelry Design Competition

Ace Entrepreneur actor artificial intelligence author Bangalore Bengaluru Blockchain technology blogger business Content Creator COVID-19 Cryptocurrency Delhi digital marketing DST Dubai education entrepreneur Gujarat health Hyderabad IIT Delhi Indian Institute of Science Indian Institute of Technology influencer Influencerquipo K Raheja Corp Homes model Mumbai music Music Industry NFT photography real estate Research Singer Social Activist Social media social media marketing Sonal Monteiro sports Surat technology TTK Prestige Zaid Khan

Copyright © 2023 The Medium News.

Powered by PressBook Blog WordPress theme